

---

## DOSIsoft and Oncosia Scientific GmbH Partner to expand PLANET® Onco Dose in Germany and Türkiye

Cachan, France | July 16, 2025

**Oncosia Scientific GmbH**, a German-based provider of dosimetry services and solutions across clinical routine, research, and trials for both diagnostic and therapeutic applications in Nuclear Medicine and **DOSIsoft SA**, leading dosimetry manufacturer specialized in patient-specific imaging and dosimetry software solutions for radiation oncology & nuclear medicine, **announce their partnership to commercialize and distribute the PLANET® Onco Dose** in German and Turkish markets.

PLANET® Onco Dose, version 3.2 is a molecular imaging, and voxel-based dosimetry solution, dedicated to Targeted Radionuclide Therapies (TRT) and now approved to be marketed in EU under CE MDR Mark.

---

Under the distribution agreement signed on March 27<sup>th</sup>, 2025, Oncosia Scientific GmbH becomes official distributor of PLANET® Onco Dose in Germany and Türkiye, and is willing to accelerate market awareness and develop business opportunities.

With a team of experienced clinical experts, including key opinion leader roles in these countries and more globally in Europe, Oncosia Scientific GmbH will provide distribution, training and support services for PLANET® Onco Dose as well as dosimetry services in the field of medical physics, clinical studies of radiopharmaceutical cancer diagnostics & therapy and routine clinical applications.

*"The recent Annual Turkish Congress of Nuclear Medicine in Antalya in which we have participated, confirmed Türkiye is a rapidly growing market where a high number of Selective Internal Radiation Therapy (**SIRT**) and Molecular Radiotherapy (**MRT**) procedures are performed annually. We see the same trend in Germany," said Nico SCHÜRRLE, CEO at Oncosia Scientific GmbH, "We're pleased to partner with DOSIsoft - a well-known dosimetry market leader, to see the German and Turkish community benefit from the latest innovation of PLANET® Onco Dose - personalized dosimetry for Radioembolization & MRT with support of radionuclides like <sup>90</sup>Y, <sup>177</sup>Lu, <sup>166</sup>Ho and <sup>131</sup>I. It further prepares Oncosia Scientific to participate as dosimetry vendor in clinical trials with a CE marked dosimetry in-house solution."*

*"We are excited to share our vision with Oncosia - elevating personalized treatment planning and dosimetry in Nuclear Medicine," highlighted Marc USZYNSKI, CEO at DOSIsoft, "This partnership creates a close collaboration regarding marketing and sales activities and a joint mission to bring the MDR-compliant and unique feature of PLANET® Onco Dose to these very important German and Turkish markets."*

### About PLANET®

PLANET® Onco Dose Edition 3 is developed by DOSIsoft SA in France. It is a Class IIb CE-marked medical device under MDR (EU) 2017/745 since February 17th, 2025 and US FDA 510(k) cleared since March 14th, 2025. Availability of the product or specific features may vary by country and regulatory approval status.

CE MDR Certificate No. 40168 was issued by GMED, a notified body with identification number CE 0459.

### About Oncosia Scientific

Oncosia Scientific GmbH is a leading provider of dosimetry services and solutions across clinical routine, research, and trials – supporting both diagnostics and targeted radionuclide treatments in nuclear medicine. With a team of experienced clinical experts, including physicians and medical physicists, we deliver evidence-based dosimetry that enhance treatment precision, safety, and patient outcomes.

**Contact** Nico SCHÜRRLE | [nico.schuerrle@oncosia.de](mailto:nico.schuerrle@oncosia.de)

Oncosia Scientific GmbH +49 (0) 160 96255919 | Dorfstr. 19, 91602 Dürnwangen - Germany

### About DOSIsoft

Founded in 2002, DOSIsoft stands as market leader specialized in dosimetry software in Radiation Oncology and Nuclear Medicine to improve cancer patient safety & treatment quality. DOSIsoft provides the most competitive patient-specific quality assurance and medical imaging solutions in over 600 hospital centers in 60 countries. Spin-off between Gustave Roussy and Curie Institute in France, DOSIsoft constantly innovates in partnership with leading cancer institutes and research centers in the world, like recently through the [Thera4Care](#) European project. [www.dosisoft.com](http://www.dosisoft.com)

**Press contact** Xiaolu CHEN | [xiaolu.chen@dosisoft.com](mailto:xiaolu.chen@dosisoft.com)

DOSIsoft SA +33 (0)1 41 24 26 26 | 45/47, Avenue Carnot, 94230 Cachan – France

DOSIsoft Inc. +1 (844) 772-3674 | 2525 Ponce de Leon Ste 300, Coral Gables, FL 33134 – USA